NCT07070440 - DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2028

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

DZD6008

DZD6008 was administered orally at 40/60/90 mg QD.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.

DRUG

Carboplatin

Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.

DRUG

Docetaxel

Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai